Targeted delivery of the CB(2) receptor agonist JWH-133 via VCAM-1-functionalised nanoparticles attenuates atherosclerosis and reveals sex-specific therapeutic outcomes.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.